Procedures have been initiated to sell or withdraw from the Medical Platform business. The counterparty, method, and timing are undecided, and the impact on consolidated results for the fiscal year ending March 2027 and beyond is under review. At this time, the full-year forecast (fiscal year ending March 2027) remains unchanged from the previously disclosed figures.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"2175","jir_company_name":"SMS Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-10-29","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/10\/2175-20261029-03.pdf","jir_short_summary":"Procedures have been initiated to sell or withdraw from the Medical Platform business. The counterparty, method, and timing are undecided, and the impact on consolidated results for the fiscal year ending March 2027 and beyond is under review. At this time, the full-year forecast (fiscal year ending March 2027) remains unchanged from the previously disclosed figures.","jir_summary":"### Review of Business Strategy and Decision to Pursue Sale\nAt the Board of Directors meeting held on October 29, 2026, it was resolved to proceed with procedures to sell or withdraw the Medical Platform business operated by the consolidated subsidiary MIMS Group to a third party. Based on the past roadmap, the aim is to maximize value under a partner with strong capital and product development capabilities and to concentrate management resources on higher capital-return businesses such as the career business and management support business. Specific details regarding counterparties, methods, and execution timing are undecided and will be promptly disclosed once determined.\n\n### Impact and Future Outlook\nThe impact of this sale or withdrawal on consolidated results for the fiscal year ending March 2027 and thereafter is currently being examined. Decisions and any effects on results will be disclosed in a timely manner once known. The consolidated earnings forecast for the fiscal year ending March 2027 remains unchanged from the figures announced on April 28, 2026.","jir_financial_highlights":"Net Sales: 71,834 million yen (Increase compared with 64,735 million yen in the previous fiscal year)\nOperating Income: 6,801 million yen (6,787 million yen in the previous fiscal year)\nOrdinary Income: 8,731 million yen (8,721 million yen in the previous fiscal year)\nNet Income Attributable to Owners of Parent: 6,165 million yen (\u25b314,317 million yen in the previous fiscal year)","jir_category":"","jir_hashtags":"#HoldOffOnShareBuybacks, #BusinessPortfolioReview","jir_key_figures":"Net Sales: 71,834 million yen\nOperating Income: 6,801 million yen\nOrdinary Income: 8,731 million yen\nNet Income Attributable to Owners of Parent: 6,165 million yen","jir_meta_title":"SMS Co., Ltd. Decides to Explore Sale of Medical Platform Business\uff5cOctober 2026","jir_meta_description":"SMS Co., Ltd. announced at a Board meeting that it will begin procedures to sell or withdraw the Medical Platform business. Counterparty, method, and timing are undecided. The impact on the fiscal year ending March 2027 is undetermined, while the policy to concentrate capital resources in line with the roadmap remains.","jir_og_title":"SMS Co., Ltd. Formally Decides to Explore Sale of Medical Platform Business","jir_og_description":"The Board has begun procedures to sell or withdraw the Medical Platform business. The scope of impact is undecided; further announcements are expected.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":9446,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"business_update","footnotes":""},"sector":[],"importance":[],"class_list":["post-136568","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n